Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-29
2011-11-22
Kosar, Andrew D (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S578000
Reexamination Certificate
active
08063040
ABSTRACT:
Novel triazabenzo[e]azulene derivatives of the formula, (I) in which R1, R2and R3have the meanings indicated in Claim1, are inhibitors of TGF-beta receptor kinase and can be employed, inter alia, for the treatment of tumors.
REFERENCES:
patent: 2318673 (1974-11-01), None
patent: 1 462 095 (1977-01-01), None
patent: 1462095 (1977-01-01), None
patent: 2007079820 (2007-07-01), None
patent: 2007008494 (2008-02-01), None
Kosychoca, L et al. “Synthesis of Substituted 5, 6-Dihydro-4H-{1,2,4}Triazolo-{4,3-a}[1,5] Benzodiazepines.” Chemistry of Heterocyclic Compounds, vol. 40, No. 6 (2004): 811-815.
Amendt Christiane
Greiner Hartmut
Hoelzemann Guenter
Kosar Andrew D
Leeser Erich A
Merck Patent Gesellschaft Mit Beschrankter Haftung
Millen White Zelano & Branigan P.C.
LandOfFree
Triazabenzo[E]azulene derivatives for the treatment of tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazabenzo[E]azulene derivatives for the treatment of tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazabenzo[E]azulene derivatives for the treatment of tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4303952